# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target...
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of ...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate o...
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company’s previously announced dispute with Juventa...
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (“CASI” or the “Company”) announced that, ...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate o...